PolyPhotonix ties up LloydsPharmacy deal
The company’s Noctura 400 sleep mask is an innovative treatment for Diabetic Retinopathy (DR), a condition which can cause sight loss.
The deal will see the mask made available to customers from the Lloyds Home Optician Service, The Outside Clinic.
LloydsPharmacy managing director, Cormac Tobin, said: “The Noctura 400 treatment bridges the gap between optometry and pharmacy and is a perfect fit with our strategic direction of providing more value added services from our high street premises.
“I am thrilled that we can offer this game changing treatment to help our diabetic patients avoid the devastating consequences of diabetic related eye disease.”
The Noctura 400 is confidently expected to replace costly current treatments, such as laser eye surgery and drug injections into the eye and could save the NHS up to £1bn.
A growing number of patients with DR have been using the mask for several months and a selection of their inspiring stories can be found on the Noctura website.
PolyPhotonix CEO Richard Kirk, who was crowned BQ’s Emerging Entrepreneur of the Year at MADE Festival last week, praised the support from Lloyds.
He said: “While traditional treatments for DR involve painful injections into the eyeball or laser therapy, our mask provides a home based, non-invasive alternative and it’s an incredible honour to be able to offer the device through the trusted household name of LloydsPharmacy.”
The revenues from the mask are being reinvested by PolyPhotonix to fund the development of other bio-photonic devices and the company has also pledged to give a share of its sales revenues to Fight for Sight, the UK’s main eye research charity that funds pioneering research to prevent sight loss and treat eye disease.